Home › Companies › Alnylam Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Alnylam Pharmaceuticals, Inc.’s Form 8-K, filed May 27, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 20, 2026: 5 items on Alnylam Pharmaceuticals, Inc.’s Form 8-K, filed May 27, 2026: 3 elected · 2 approved.
Notable dissent: 1 director (10.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Alnylam Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Alnylam Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 27, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Stuart A. Arbuckle | 115,269,659 | 5,068,463 | 28,296 | -- | 5,450,286 | 96% | Elected | — |
| Elect Director: Yvonne L. Greenstreet, M.D. | 119,787,307 | 513,049 | 66,062 | -- | 5,450,286 | 99.6% | Elected | — |
| Elect Director: Elliott Sigal, M.D., Ph.D. | 107,495,421 | 12,844,836 | 26,161 | -- | 5,450,286 | 89% | Elected | — |
| 2. Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting | 111,772,389 | 8,552,534 | 41,495 | -- | 5,450,286 | 93% | Approved | — |
| 3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 | 119,847,735 | 5,937,274 | 31,695 | -- | 0 | 95% | Approved | — |
Source: Alnylam Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 27, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
714 asset managers disclosed a vote on at least one Alnylam Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D.
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Elliott Sigal, M.D., Ph.D.”): 107,495,421 for, 12,844,836 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 155 asset managers below reported 68,794,831 for, 5,761,800 against, 9,950 abstained, 112 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,186 | 103 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 4,184,185 | 0 | 0 | Against |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 408,600 | 610,709 | 0 | 0 | Mixed |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 944 | 332,986 | 0 | 0 | Against |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 193,366 | 38,126 | 0 | 0 | Mixed |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 155 asset managers. All 155 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Stuart A. Arbuckle
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Stuart A. Arbuckle”): 115,269,659 for, 5,068,463 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 155 asset managers below reported 70,281,402 for, 4,275,228 against, 9,950 abstained, 112 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,245 | 44 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 991,003 | 3,193,182 | 0 | 0 | Mixed |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 408,600 | 610,709 | 0 | 0 | Mixed |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,930 | 0 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 231,492 | 0 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 155 asset managers. All 155 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Yvonne L. Greenstreet, M.D.
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Yvonne L. Greenstreet, M.D.”): 119,787,307 for, 513,049 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 155 asset managers below reported 74,494,553 for, 62,075 against, 9,950 abstained, 112 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,284 | 3 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,184,185 | 0 | 0 | 0 | For |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,930 | 0 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 201,362 | 30,130 | 0 | 0 | Mixed |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 155 asset managers. All 155 are in the interactive database (link above).
Combines 19 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“2. The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting”): 111,772,389 for, 8,552,534 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,243 | 46 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,975,770 | 208,415 | 0 | 0 | For |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,392,831 | 508,061 | 0 | 0 | Mixed |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,930 | 0 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 231,492 | 0 | 0 | 0 | For |
| Lincoln Financial | 143,405 | 76,650 | 0 | 0 | Mixed |
Fund voting reports, all 150 managers: 73,699,593 for, 843,838 against, 9,950 abstained, 112 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,084,931 | 0 | 0 | 0 | For |
| Capital Group | 10,822,295 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 9,449,428 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,282,021 | 310,421 | 0 | 0 | For |
| BlackRock | 5,511,004 | 0 | 0 | 0 | For |
| State Street | 2,779,286 | 3,361 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,670,197 | 0 | 0 | 0 | For |
| Wellington | 1,852,421 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,815,428 | 0 | 0 | 0 | For |
| American Century | 1,605,554 | 0 | 0 | 0 | For |
| Vanguard | 1,199,059 | 0 | 0 | 0 | For |
| Orbis Allan Gray Ltd | 1,134,001 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 1,113,021 | 0 | 0 | 0 | For |
| Invesco | 85,524 | 835,972 | 0 | 0 | Mixed |
| BAILLIE GIFFORD & CO LTD | 871,986 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 809,469 | 0 | 0 | 0 | For |
| Northern Trust | 752,082 | 0 | 0 | 0 | For |
| Charles Schwab | 737,661 | 0 | 0 | 0 | For |
| Two Sigma | 696,784 | 0 | 0 | 0 | For |
| Federated Hermes | 673,603 | 4,088 | 0 | 0 | For |
| DE Shaw | 602,674 | 0 | 0 | 0 | For |
| Amundi | 0 | 579,094 | 0 | 0 | Against |
| Legal & General Investment Management Ltd | 0 | 558,570 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 556,881 | 0 | 0 | 0 | For |
| JPMorgan | 523,476 | 0 | 0 | 0 | For |
Institutional-manager reports, all 599 managers: 81,439,339 for, 4,809,109 against, 91 abstained, 11,212 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 94.8% for (May 8, 2025 meeting) ▲ 0.5 pts
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2026.
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026”): 119,847,735 for, 5,937,274 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 155 asset managers below reported 73,845,890 for, 710,740 against, 9,950 abstained, 112 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,088,432 | 659,857 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,184,185 | 0 | 0 | 0 | For |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,919 | 11 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 231,492 | 0 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 155 asset managers. All 155 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of May 8, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 132,376,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.14% |
| 2 | Fidelity | 9.85% |
| 3 | Capital Group | 9.59% |
| 4 | T. Rowe Price | 3.16% |
| 5 | BlackRock | 3.04% |
| 6 | Invesco | 2.95% |
| 7 | JPMorgan | 2.88% |
| 8 | AMCAP FUND | 2.83% |
| 9 | INVESTMENT CO OF AMERICA | 1.47% |
| 10 | Dodge & Cox | 1.11% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 10.64% |
| 2 | Capital Group | 8.18% |
| 3 | Capital Research Global Investors | 7.14% |
| 4 | T. Rowe Price | 4.98% |
| 5 | BlackRock | 4.16% |
| 6 | State Street | 2.10% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.02% |
| 8 | Wellington | 1.40% |
| 9 | Dodge & Cox | 1.37% |
| 10 | American Century | 1.21% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 14,579,166 | 11.01% | Form 13F, quarter ended March 31, 2026 |
| Capital World Investors | 10,916,799 | 8.25% | Schedule 13G, filed May 14, 2026 |
| BlackRock | 10,444,908 | 7.89% | Form 13F, quarter ended March 31, 2026 |
| Capital Research Global Investors | 9,471,181 | 7.15% | Schedule 13G, filed May 14, 2026 |
| JPMorgan Chase | 6,323,752 | 4.78% | Form 13F, quarter ended March 31, 2026 |
| State Street | 3,322,698 | 2.51% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 1,992,577 | 1.51% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management | 1,935,925 | 1.46% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 1,474,362 | 1.11% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 1,432,748 | 1.08% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 132,376,000 shares outstanding, as reported by Alnylam Pharmaceuticals, Inc. on its Form 10-K dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Alnylam Pharmaceuticals, Inc.'s shareholder meeting held May 20, 2026, in the 2025-2026 proxy season, 714 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 4,710 separate fund positions. On the most widely held item on that ballot — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — Alnylam Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Alnylam Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 27, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Alnylam Pharmaceuticals, Inc.’s 10-K dated December 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Alnylam Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Alnylam Pharmaceuticals (ALNY) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/alnylam-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.